Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
- Income Statement
- Cash Flow Statement
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Operating Profit Margin since 2005
- Total Asset Turnover since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Revenues
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
- Current Ratio
- The current ratio demonstrated a fluctuating but generally high level throughout the observed periods. Starting at 7.07 in March 2018, it climbed to a peak of 15.2 by December 2020. After this peak, the ratio showed a notable decline into mid-2021, falling to 5.9 in June 2021. Subsequent quarters witnessed a recovery, with values rising again to reach 11.56 in September 2022 before declining to 7.22 by September 2023. These fluctuations indicate variability in the company's short-term liquidity management, with substantial increases followed by intermittent decreases but maintaining a position well above standard benchmarks for liquidity.
- Quick Ratio
- The quick ratio tracked a trend similar to the current ratio across the quarters. Beginning at 6.52 in March 2018, it reached its highest point at 15.06 in September 2020. A sharp decrease occurred in the first half of 2021, bottoming near 5.72 in March 2021 before rebounding above 11 in September 2022. Thereafter, it gradually decreased again to 6.97 by September 2023. The quick ratio's pattern suggests consistent but fluctuating capacity to cover immediate liabilities without relying on inventory, aligning closely with the movements observed in the current ratio.
- Cash Ratio
- The cash ratio also shows a pattern closely mirroring both the current and quick ratios. From a starting value of 6.52 in March 2018, it increased steadily until reaching a maximum of approximately 14.88 in September 2020. This was followed by a pronounced drop to around 5.67 in March 2021. Recovery phases were evident in late 2021 through 2022, with the ratio climbing above 11 in September 2022 before a decline to 6.94 by the latest quarter in September 2023. This ratio's movement confirms variations in the company's most liquid assets available relative to current liabilities, with substantial accessibility before the mid-2021 decrease and moderate liquidity in the latest periods.
- Overall Insights
- Across all three liquidity ratios, the company exhibited strong short-term financial positions with ratios well above 1 throughout the entire period, indicating ample liquidity. The years 2019 and early 2020 showed increasing liquidity levels, peaking around the third and fourth quarters of 2020. However, the first half of 2021 marked a considerable decline in all liquidity measures. Subsequent quarters experienced gradual recovery phases, though none reached previous peaks, and a downward trend is noticed again by the third quarter of 2023. These dynamics may reflect changes in operational cycles, asset management strategies, or shifts in current liabilities.
Current Ratio
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Current assets | ||||||||||||||||||||||||||||||
Current liabilities | ||||||||||||||||||||||||||||||
Liquidity Ratio | ||||||||||||||||||||||||||||||
Current ratio1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
Current Ratio, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends in the company's current assets, current liabilities, and current ratio over the observed periods.
- Current Assets
- Current assets display fluctuations throughout the time span, starting at approximately 272 million US dollars in Q1 2018 and generally trending downward until the end of 2018, reaching a low near 207 million. From early 2019, the values oscillate with a slight upward momentum, notably increasing in Q4 2020 to over 474 million. Following this peak, a moderate decline occurs in 2021, but then there is consistent growth from early 2022 onward, culminating at approximately 884 million US dollars in Q1 2023. However, subsequent quarters in 2023 show a gradual decrease, ending the period at around 561 million.
- Current Liabilities
- Current liabilities start at about 38.5 million in Q1 2018, sharply decreasing in the first few quarters to roughly 21–27 million range through 2018 and 2019. An upward trend becomes evident starting in 2021, with liabilities rising significantly to peak near 80.9 million in Q3 2021. This is followed by some volatility, but the liabilities remain elevated relative to prior years, fluctuating between approximately 65 million and 85 million in 2022 and 2023. The increase in liabilities during this latter period suggests a shift in short-term obligations.
- Current Ratio
- The current ratio exhibits high values overall, indicating strong short-term liquidity. Initially, the ratio rises from 7.07 in Q1 2018 to a peak of 10.57 in Q3 2018, then maintains a range generally above 7 through 2019. A pronounced increase occurs in 2020, with the ratio reaching about 15.2 in Q4 2020, which corresponds with the spike in current assets and a relatively contained increase in liabilities. However, in 2021, the ratio declines sharply, dropping to approximately 5.9 in Q1 2021 and staying below earlier high values, reflecting rising current liabilities and somewhat reduced current assets during this period. The ratio then improves again across 2022, reaching above 11.5 in Q3 2022, before trending down modestly toward 7.22 by Q3 2023.
In summary, the company exhibited strong liquidity as indicated by high current ratios throughout most periods, with significant growth in current assets observed especially from late 2020 through early 2023. Concurrently, current liabilities increased markedly after 2020, impacting liquidity ratios notably in 2021 before partial recovery. The fluctuations suggest changes in operational or financing activities affecting working capital management, highlighting periods of increased short-term obligations alongside efforts to bolster asset bases.
Quick Ratio
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Cash and cash equivalents | ||||||||||||||||||||||||||||||
Short-term investments | ||||||||||||||||||||||||||||||
Accounts receivable | ||||||||||||||||||||||||||||||
Total quick assets | ||||||||||||||||||||||||||||||
Current liabilities | ||||||||||||||||||||||||||||||
Liquidity Ratio | ||||||||||||||||||||||||||||||
Quick ratio1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
Quick Ratio, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
- Total Quick Assets
- The total quick assets demonstrated a fluctuating trend over the examined periods. Initially, there was a decline from approximately 251.5 million USD at the end of Q1 2018 to a lower point near 172.6 million USD in Q3 2019. This was followed by a significant recovery and growth peaking at around 869.9 million USD in Q1 2022. Subsequent quarters showed a decreasing pattern but still maintained higher levels relative to the 2018-2019 range, ending with about 541.7 million USD in Q3 2023.
- Current Liabilities
- Current liabilities exhibited moderate fluctuations but remained within a relatively narrower band than total quick assets. Starting near 38.5 million USD in Q1 2018, these liabilities decreased to a low close to 21.5 million USD by Q3 2018. Thereafter, liabilities increased and peaked around 80.9 million USD in late 2021, followed by a slight decline and some variability, closing at approximately 77.7 million USD in Q3 2023. Overall, liabilities rose significantly in the middle part of the observed timeframe, before stabilizing at a higher level than the earlier years.
- Quick Ratio
- The quick ratio showed considerable variation, reflecting changes in liquidity relative to current liabilities. Initially, it increased from 6.52 in Q1 2018 to a peak of 10.21 in Q3 2018, followed by some oscillations before a marked rise reaching 15.06 in Q3 2020. Afterward, the ratio declined sharply to near 5.72 in Q2 2021 but rose again to 11.37 by Q1 2022. The ratio then gradually decreased across subsequent quarters, ending at 6.97 in Q3 2023. This pattern indicates periods of strong liquidity interspersed with notable decreases, suggesting variability in the company's short-term financial stability across the assessed periods.
- Summary
- Overall, the financial data reveals a dynamic pattern in the company’s liquidity and liabilities. The total quick assets show growth with intermittent declines, often accompanied by increases in current liabilities. The quick ratio's fluctuations signal changing liquidity conditions, with phases of strong short-term asset coverage against liabilities transitioning to periods of reduced liquidity. The data suggests that while the company achieved significant increases in quick assets, particularly around 2020 and early 2022, it also faced periods where current liabilities and liquidity ratios posed challenges to financial stability.
Cash Ratio
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Cash and cash equivalents | ||||||||||||||||||||||||||||||
Short-term investments | ||||||||||||||||||||||||||||||
Total cash assets | ||||||||||||||||||||||||||||||
Current liabilities | ||||||||||||||||||||||||||||||
Liquidity Ratio | ||||||||||||||||||||||||||||||
Cash ratio1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
Cash Ratio, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
- Total Cash Assets
- The total cash assets display a general pattern of fluctuations with some distinct periods of increase and decrease. From early 2018 to the end of 2019, cash assets showed a declining trend, moving from approximately $251 million to around $225 million, with minor intermittent falls. However, starting in early 2020, there is a notable surge in cash assets, rising sharply to reach a peak of about $464 million by the end of 2020. Following this peak, the cash assets exhibit variability, with sizeable increases and decreases through 2021 and early 2022, hitting the highest value in the series around $868 million in the first quarter of 2022. After this peak, a gradual decline is observed across subsequent quarters into late 2023, though the levels remain significantly above the earlier years' figures.
- Current Liabilities
- Current liabilities present a more stable yet upward-trending pattern over the period. Beginning around $38.5 million in early 2018, liabilities dropped initially to below $22 million by late 2018, signaling a reduction in short-term financial obligations. From 2019 onwards, there is a steady increase in liabilities, with occasional spikes such as in mid-2021 where liabilities surged to over $80 million. Despite fluctuations, the overall trend indicates a roughly doubling of current liabilities from the start to the end of the observed period, reaching around $78 million by late 2023.
- Cash Ratio
- The cash ratio exhibits variability consistent with movements in cash assets and current liabilities. Early 2018 shows relatively high liquidity values above 6x, with peaks approaching nearly 10x by late 2018. The ratio peaked notably during 2020, reaching nearly 15x, reflecting an exceptionally strong liquidity position likely driven by high cash reserves and controlled liabilities during this period. However, from mid-2021 onwards, the ratio generally declines, dropping below 7x towards the end of 2023. Despite the decline, the ratio remains well above 1, indicating the company's cash position sufficiently covers its current liabilities throughout the entire period.
- Overall Trends and Insights
- The data suggests the company experienced significant cash accumulation starting in early 2020, possibly reflecting operational changes, fundraising, or other liquidity-enhancing activities. This increase in cash assets outpaced the growth in current liabilities, resulting in very high liquidity ratios through 2020 and early 2021. However, a gradual normalization phase occurs after this peak, where cash assets decrease and liabilities rise, leading to lower liquidity ratios, though still maintaining comfortable coverage of short-term obligations. The rising current liabilities imply either increased short-term financing or operational expenditures. The strong liquidity levels throughout the period indicate prudent cash management and a stable financial position with the ability to cover liabilities multiple times over.